<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331315</url>
  </required_header>
  <id_info>
    <org_study_id>12-02041-FB</org_study_id>
    <nct_id>NCT03331315</nct_id>
  </id_info>
  <brief_title>Toradol v. Celecoxib for Postoperative Pain</brief_title>
  <acronym>POP</acronym>
  <official_title>A Randomized Control Trial Study of the Efficacy of Celecoxib Versus Ketorolac for Perioperative Pain Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee Health Science Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee Health Science Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized control trial between ketorolac versus celecoxib for postoperative pain following
      hysterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      To determine if Celebrex (Celecoxib) is as effective as Toradol (Ketorolac) at controlling
      postoperative pain when given in addition to standard postoperative pain control regimens.

      Rationale:

      Toradol (Ketorolac) is currently used by many surgeons as adjuvant therapy in addition to
      standard narcotics in managing immediate postoperative pain. Toradol (Ketorolac) is a
      non-steroidal anti-inflammatory drug that acts as a non-selective cyclooxygenase (COX),
      inhibiting COX-1 and COX-2 isoforms. (Toradol) Ketorolac has been associated with significant
      complications including postoperative bleeding and acute renal insufficiency. Celebrex
      (Celecoxib) is a selective COX-2 inhibitor that has been associated with adverse
      cardiovascular outcomes in patients with pre-existing cardiac disease but not with
      postoperative bleeding or renal insufficiency. Celebrex (Celecoxib) has also been shown to
      control postoperative pain but has never been compared to Toradol (Ketorolac).

      Population:

      Patients undergoing hysterectomy on the gynecology oncology service.

      Design:

      Randomized control trial.

      Procedures:

      All patients will receive a standard posteroperative pain regimen with oral Tylenol
      (Acetaminophen), oral Lortab (Hydrocodone/Acetaminophen) as needed, and IV Diludid
      (Hydromorphone) as needed.

      Randomization: Each participant will be assigned a number using a random number generator for
      assignment to one of the two postoperative pain regimens:

      Arm 1:

      Patients ages 18-65 will receive IV Toradol (Ketorolac) 30mg q6 hrs after their operation for
      48 hrs or until hospital discharge if patients are discharged home in less than 48 hours
      after their operation.

      **Patients over age 65 will receive IV Toradol (Ketorolac) 15mg q6hrs instead of 30mg

      Arm 2:

      Patients who will receive oral Celebrex (Celecoxib) 400mg 1 hour prior to their procedure
      then 200mg oral twice daily for a total of seven days. Patients discharged prior to 7 days
      will be given a prescription for Celebrex (Celecoxib) to complete a total of 7 days.

      Following surgery all patients will be given a postoperative questionnaire at the day of
      surgery, which was returned at the two week postoperative visit, examining time until return
      to ADLs, days of narcotic use, and number of narcotic pills used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2013</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Inpatient Postoperative Pain Score</measure>
    <time_frame>48 hrs following surgery</time_frame>
    <description>Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Inpatient Hydromorphone Use</measure>
    <time_frame>48 hrs following surgery</time_frame>
    <description>Average inpatient hydromorphone use measured in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Inpatient Ondansetron Use</measure>
    <time_frame>48 hrs following surgery</time_frame>
    <description>Average inpatient ondansetron use measured in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hospital Stay</measure>
    <time_frame>Following surgery</time_frame>
    <description>Total hospital stay from time fo admission to time of discharge measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perioperative Complications</measure>
    <time_frame>During and after surgery</time_frame>
    <description>Perioperative Complications measured intraoperatively and postoperatively by type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to Activities of Daily Living</measure>
    <time_frame>2 weeks after discharge</time_frame>
    <description>Average number of days required for complete return to independent activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Oral Narcotic Use After Discharge</measure>
    <time_frame>2 weeks after discharge</time_frame>
    <description>Measured using postoperative questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Oral Narcotic Pills Used After Discharge</measure>
    <time_frame>2 weeks after discharge</time_frame>
    <description>Number of oral narcotic pills used after discharge until 2 week postoperative visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving scheduled ketorolac postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving celebrex preoperative and postoperatively for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <arm_group_label>Ketorolac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing hysterectomy

        Exclusion Criteria:

          -  Coronary Artery Disease

          -  Peptic Ulcer Disease

          -  Chronic Renal Disease

          -  Liver disease

          -  Alcohol Abuse

          -  Daily narcotic usage

          -  Narcotic use 24 hours prior to surgery

          -  Crohn's Disease

          -  History of myocardial infarction

          -  History of stroke

          -  Preoperative hematocrit less than 24

          -  Asthma

          -  Ulcerative Colitis

          -  Diverticulitis

          -  Aspirin Allergy

          -  Sulfonamide Allergy

          -  Pre-operative pain score of greater than 3

          -  Patients undergoing procedures that may involve bowel resection or bowel
             reanastomisis.

          -  Allergy to any non-steroidal anti-inflammatory drug

          -  Cardiac anomaly or disease

          -  Congestive Heart Failure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Ulm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Science Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Hospital System</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Azari L, Santoso JT, Osborne SE. Optimal pain management in total abdominal hysterectomy. Obstet Gynecol Surv. 2013 Mar;68(3):215-27. doi: 10.1097/OGX.0b013e31827f5119. Review.</citation>
    <PMID>23945838</PMID>
  </reference>
  <reference>
    <citation>Blanton E, Lamvu G, Patanwala I, Barron KI, Witzeman K, Tu FF, As-Sanie S. Non-opioid pain management in benign minimally invasive hysterectomy: A systematic review. Am J Obstet Gynecol. 2017 Jun;216(6):557-567. doi: 10.1016/j.ajog.2016.12.175. Epub 2016 Dec 30. Review.</citation>
    <PMID>28043841</PMID>
  </reference>
  <reference>
    <citation>Strom BL, Berlin JA, Kinman JL, Spitz PW, Hennessy S, Feldman H, Kimmel S, Carson JL. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996 Feb 7;275(5):376-82.</citation>
    <PMID>8569017</PMID>
  </reference>
  <reference>
    <citation>Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb.</citation>
    <PMID>22336956</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>March 29, 2018</results_first_submitted>
  <results_first_submitted_qc>April 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2018</results_first_posted>
  <last_update_submitted>June 1, 2018</last_update_submitted>
  <last_update_submitted_qc>June 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tennessee Health Science Center</investigator_affiliation>
    <investigator_full_name>Michael Ulm</investigator_full_name>
    <investigator_title>Priniciple Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac</title>
          <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
        </group>
        <group group_id="P2">
          <title>Celecoxib</title>
          <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac</title>
          <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
        </group>
        <group group_id="B2">
          <title>Celecoxib</title>
          <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.3" spread="11.3"/>
                    <measurement group_id="B2" value="55.1" spread="14.4"/>
                    <measurement group_id="B3" value="55.7" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="8.6"/>
                    <measurement group_id="B2" value="31.7" spread="8.1"/>
                    <measurement group_id="B3" value="31.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical Pathology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Benign</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Malignant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Procedure</title>
          <description>BSO - bilateral salpingo-oophorectomy LND - Lymph Node Dissection Cysto - diagnostic cystoscopy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Robotic Assisted Hysterectomy, +/- BSO, Cysto</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Robotic Assisted Hysterectomy, +/- BSO, LND, Cysto</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Operative Time</title>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105" spread="32"/>
                    <measurement group_id="B2" value="104" spread="34"/>
                    <measurement group_id="B3" value="104" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trochar Sites</title>
          <units>Trochars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="0.5"/>
                    <measurement group_id="B2" value="4.2" spread="0.4"/>
                    <measurement group_id="B3" value="4.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Malignancy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Premalignancy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Leiomyoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pelvic Pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal Uterine Bleeding</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adnexal Mass</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Genetic Predisposition to Malignancy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Inpatient Postoperative Pain Score</title>
        <description>Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff.</description>
        <time_frame>48 hrs following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Average Inpatient Postoperative Pain Score</title>
          <description>Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.9"/>
                    <measurement group_id="O2" value="2.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Inpatient Hydromorphone Use</title>
        <description>Average inpatient hydromorphone use measured in milligrams</description>
        <time_frame>48 hrs following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Average Inpatient Hydromorphone Use</title>
          <description>Average inpatient hydromorphone use measured in milligrams</description>
          <units>Milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.0"/>
                    <measurement group_id="O2" value="0.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Inpatient Ondansetron Use</title>
        <description>Average inpatient ondansetron use measured in milligrams</description>
        <time_frame>48 hrs following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Average Inpatient Ondansetron Use</title>
          <description>Average inpatient ondansetron use measured in milligrams</description>
          <units>Milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.9"/>
                    <measurement group_id="O2" value="1.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hospital Stay</title>
        <description>Total hospital stay from time fo admission to time of discharge measured in hours</description>
        <time_frame>Following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hospital Stay</title>
          <description>Total hospital stay from time fo admission to time of discharge measured in hours</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="8.1"/>
                    <measurement group_id="O2" value="11.9" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perioperative Complications</title>
        <description>Perioperative Complications measured intraoperatively and postoperatively by type</description>
        <time_frame>During and after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Participants</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perioperative Complications</title>
          <description>Perioperative Complications measured intraoperatively and postoperatively by type</description>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Return to Activities of Daily Living</title>
        <description>Average number of days required for complete return to independent activities of daily living</description>
        <time_frame>2 weeks after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Return to Activities of Daily Living</title>
          <description>Average number of days required for complete return to independent activities of daily living</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.8"/>
                    <measurement group_id="O2" value="2.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Oral Narcotic Use After Discharge</title>
        <description>Measured using postoperative questionnaire</description>
        <time_frame>2 weeks after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Oral Narcotic Use After Discharge</title>
          <description>Measured using postoperative questionnaire</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="2.8"/>
                    <measurement group_id="O2" value="3.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Oral Narcotic Pills Used After Discharge</title>
        <description>Number of oral narcotic pills used after discharge until 2 week postoperative visit.</description>
        <time_frame>2 weeks after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib</title>
            <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oral Narcotic Pills Used After Discharge</title>
          <description>Number of oral narcotic pills used after discharge until 2 week postoperative visit.</description>
          <units>Pills</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="4.0"/>
                    <measurement group_id="O2" value="6.0" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketorolac</title>
          <description>Patients receiving scheduled ketorolac postoperatively
Ketorolac</description>
        </group>
        <group group_id="E2">
          <title>Celecoxib</title>
          <description>Patients receiving celebrex preoperative and postoperatively for 7 days
Celecoxib</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Intraoperative Hemorrhage</sub_title>
                <description>Estimated Blood Loss &gt;150cc</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <description>Transient acute kidney injury, resolved with IV hydration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Ulm</name_or_title>
      <organization>University of Tennessee - West Cancer Center</organization>
      <phone>404-281-9480</phone>
      <email>mulm@westclinic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

